Zydus Lifesciences Gets USFDA Approval for Generic Arthritis Drug
May 11, 2024 16:27
Zydus Lifesciences receives USFDA approval to market Dexamethasone tablets (1mg) for arthritis, blood disorders, and other conditions in the US.
New Delhi, May 11 (PTI) Zydus Lifesciences on Saturday said it has received approval from the US health regulator to market a generic medication for arthritis and other conditions in the American market.
The company has received final approval from the US Food and Drug Administration (USFDA) to market Dexamethasone tablets (1mg), the drug maker said in a statement.
Dexamethasone is used to treat conditions like arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer and immune system disorders.
As per IQVIA data, Dexamethasone tablets had an annual sales of USD 1.8 million in the US.
DISCLAIMER - This article is from a syndicated feed. The original source is responsible for accuracy, views & content ownership. Views expressed may not reflect those of rediff.com India Limited.